Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spot hidden clots from central lines in critical care

NCT ID NCT06094387

Diagnosis Sponsor: Queen Mary Hospital, Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This study tests whether a blood test called a thrombin generation assay can detect central line related thrombosis, a blood clot that forms around a central catheter, in critically ill patients. Researchers will compare clotting activity in ICU patients who develop these clots versus those who do not. The goal is to see if this test could help identify clots earlier and improve patient safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Thrombin generation assay, a blood test measuring clotting activity
What this could lead to
If the test works, it could help doctors spot central line related blood clots earlier in ICU patients, potentially preventing complications.
What could go wrong
This is a very small early study with only 2 participants, so results may not apply broadly. The test may not reliably distinguish who develops clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2 people

The number who actually took part.

Started

Apr 2024

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients requiring central catheter insertion in the ICU

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≧ 18; AND * Admitted to the mixed medical-surgical intensive care units of Queen Mary Hospital in Hong Kong; AND * Clinically indicated for central catheter insertion, which includes central venous catheters and dialysis catheters; AND * Expected to have the central catheter in place for at least 5 days in their ICU stay. Exclusion Criteria: * Patients known to have active venous thromboembolism including deep venous thrombosis or pulmonary embolism; * Patients known to have hypercoagulable states, e.g., hereditary thrombophilia, antiphospholipid syndrome; OR * Patients with active solid organ or hematological malignancies; OR * Patients already receiving therapeutic anticoagulation prior to study recruitment; OR * Patients with thrombosis detected in the insertion site before central catheter insertion; OR * Patients with a central venous catheter already in place prior to ICU admission; OR * Patients admitted to the ICU for post-operative care; OR * Patients admitted to the ICU for trauma care; OR * Patients requiring extra-corporeal life support (ECLS); OR * Patients with poor window or inaccessible for ultrasonographic examination; OR * Pregnancy/post-partum within 6 weeks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Central line complication are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Central line complication Thrombosis, venous

Contacts and locations

Locations

  • Queen Mary Hospital

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.